Advertisement

Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes

  • Tyler T. Tinkham
  • Sara R. VazquezEmail author
  • Aubrey E. Jones
  • Daniel M. Witt
Article
  • 32 Downloads

Abstract

Concurrent antiplatelet therapy (APT) is common during warfarin therapy but is less well-documented during direct oral anticoagulant (DOAC) therapy. Combined anticoagulant and APT use has been associated with increased bleeding risk without providing additional protection against thrombosis. This study aimed to describe single-center prescribing rates of DOAC + APT as well as compare bleeding rates between DOAC monotherapy and DOAC + APT cohorts. Patients receiving DOAC therapy were evaluated for APT use at the time of hospital discharge. Patients were categorized into DOAC monotherapy and DOAC + APT cohorts. Primary outcomes included DOAC + APT prescribing rate as well as rates of major bleeding and clinically relevant non-major bleeding (CRNMB) within six months after hospital discharge. Secondary outcomes included rates of thromboembolism and all-cause mortality. Of 407 patients receiving DOAC therapy, 78 (19.2%) also received APT at hospital discharge. Common indications for APT included secondary cardiovascular event prevention (57.7%) and primary cardiovascular event prevention (29.5%). The indication for APT could not be determined in 12.8% of patients. The major bleeding rate was 1.3% for DOAC + APT and 1.2% for DOAC monotherapy (p = 0.95). The CRNMB rate was 10.2% for DOAC + APT and 6.4% for DOAC monotherapy (p = 0.23). Thromboembolism and mortality were infrequent in both cohorts. DOAC + APT was documented in approximately 1 of 5 patients. Adding APT to DOAC therapy did not significantly increase the major bleeding or CRNMB rates compared to DOAC monotherapy but the sample size limits drawing conclusions about the safety of these regimens. Targeting primary prevention or unclear indications for APT could be a focus of future interventions.

Keywords

Direct oral anticoagulant Antiplatelet Aspirin Bleeding 

Notes

Acknowledgements

The authors would like to acknowledge Stacy A. Johnson, MD for assistance with data retrieval.

Funding

This study received no external funding.

Compliance with ethical standards

Conflict of interest

Sara R. Vazquez declares that she is an editorial consult for UpToDate® and a member of the Anticoagulation Forum Board of Directors. Daniel M. Witt declares that he is a member of the Anticoagulation Forum Advisory Council and has received grant funding unrelated to this study from Roche Diagnostics Corporation (RD003737). The other authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of Utah Institutional Review Board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Due to the retrospective chart review design of the study, the University of Utah Institutional Review Board waived the requirement for informed consent.

References

  1. 1.
    Cullen MW, Kim S, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, Singer DE, Mahaffey KW, Kowey PR, Thomas L, Go AS, Lopes RD, Chang P, Peterson ED, Gersh BJ, ORBIT-AF Investigators (2013) Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes 6:461–469.  https://doi.org/10.1161/CIRCOUTCOMES.113.000127 CrossRefPubMedGoogle Scholar
  2. 2.
    Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S (2013) Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127:634–640.  https://doi.org/10.1161/CIRCULATIONAHA.112.115386 CrossRefPubMedGoogle Scholar
  3. 3.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ORBIT-AF Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891.  https://doi.org/10.1056/NEJMoa1009638 CrossRefGoogle Scholar
  4. 4.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992.  https://doi.org/10.1056/NEJMoa1107039 CrossRefGoogle Scholar
  5. 5.
    Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, Shi M, Mercuri M, Antman EM, Braunwald E (2016) Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc 5(2):e002587.  https://doi.org/10.1161/JAHA.115.002587 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Majeed A, Goldhaber SZ, Kakkar A, Kearon C, Eriksson H, Kreuzer J, Feuring M, Hantel S, Friedman J, Schellong S, Schulman S (2016) Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thromb Haemost 115:291–298.  https://doi.org/10.1160/TH15-04-0319 CrossRefPubMedGoogle Scholar
  7. 7.
    Cohen AT, Agnelli G, Buller HR, Gallus A, Raskob GE, Sanders P, Thompson J, Weitz JI (2019) Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thromb Haemost 119:461–466.  https://doi.org/10.1055/s-0038-1676983 CrossRefPubMedGoogle Scholar
  8. 8.
    Di Nisio M, Raskob G, Büller HR, Grosso MA, Zhang G, Winters SM, Cohen A (2017) Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost 117:784–793.  https://doi.org/10.1160/TH16-11-0830 CrossRefPubMedGoogle Scholar
  9. 9.
    van Rein N, Heide-Jørgensen U, Lijfering WM, Dekkers OM, Sørensen HT, Cannegieter SC (2019) Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation 139:775–786.  https://doi.org/10.1161/CIRCULATIONAHA.118.036248 CrossRefPubMedGoogle Scholar
  10. 10.
    Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L (2018) Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 154:1121–1201.  https://doi.org/10.1016/j.chest.2018.07.040 CrossRefPubMedGoogle Scholar
  11. 11.
    January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 140:e125–e151.  https://doi.org/10.1161/CIR.0000000000000665 CrossRefPubMedGoogle Scholar
  12. 12.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L (2016) Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 149:315–352.  https://doi.org/10.1016/j.chest.2015.11.026 CrossRefPubMedGoogle Scholar
  13. 13.
    Deitelzweig S, Farmer C, Luo X, Li X, Vo L, Mardekian J, Fahrbach K, Ashaye A (2018) Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Curr Med Res Opin 34:487–498.  https://doi.org/10.1080/03007995.2017.1411793 CrossRefPubMedGoogle Scholar
  14. 14.
    Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M (2015) Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 13:2012–2020.  https://doi.org/10.1111/jth.13139 CrossRefPubMedGoogle Scholar
  15. 15.
    Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH, AUGUSTUS Investigators (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509–1524.  https://doi.org/10.1056/NEJMoa1817083 CrossRefPubMedGoogle Scholar
  16. 16.
    Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH, RE-DUAL PCI Steering Committee and Investigators (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513–1524.  https://doi.org/10.1056/NEJMoa1708454 CrossRefPubMedGoogle Scholar
  17. 17.
    Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423–2434.  https://doi.org/10.1056/NEJMoa1611594 CrossRefPubMedGoogle Scholar
  18. 18.
    Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8:202–204.  https://doi.org/10.1111/j.1538-7836.2009.03678.x CrossRefPubMedGoogle Scholar
  19. 19.
    Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B (2019) 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140(11):e596–e646.  https://doi.org/10.1161/CIR.0000000000000678 CrossRefPubMedGoogle Scholar
  20. 20.
    Schaefer JK, Li Y, Gu X, Souphis NM, Haymart B, Kline-Rogers E, Almany SL, Kaatz S, Kozlowski JH, Krol GD, Sood SL, Froehlich JB, Barnes GD (2019) Association of adding aspirin to warfarin therapy without an apparent indication with bleeding and other adverse events. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2018.7816 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of PharmacotherapyUniversity of Utah College of PharmacySalt Lake CityUSA
  2. 2.University of Utah Health Thrombosis CenterSalt Lake CityUSA
  3. 3.University of Utah Health Thrombosis CenterSalt Lake CityUSA

Personalised recommendations